Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
irsogladine maleate + nizatidine
- Development stage
- Preclinical
- Lead developer
- Boryung
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
A combination therapy consisting of irsogladine maleate, a mucoprotective agent, and nizatidine, an H2-receptor antagonist. This combination targets both gastric mucosal protection and acid suppression, making it effective for treating erosive gastritis and other gastric conditions. The synergistic approach enhances treatment outcomes compared to monotherapy with either agent alone.
02
Targets
HRH2 (Histamine H2 Receptor)
Beyond the preview
Go deeper on irsogladine maleate + nizatidine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on irsogladine maleate + nizatidine.